Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361981 | 0.90 | CASP3 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL7423417 | 0.90 | CASP3 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29423514 | 0.90 | CASP3 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29386346 | 0.90 | CASP3 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL13163967 | 0.90 | CASP3 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL2313063 | 0.90 | CASP3 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30141988 | 0.90 | MDM4 (0.54) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29991547 | 0.89 | CASP3 (0.53) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL15083369 | 0.86 | MDM4 (0.49) | MDM4TP53CASP3 | |
| SCHEMBL29380066 | 0.86 | MDM4 (0.57) | MDM4TP53CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276995-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-04 | — | — | US | disclosed |
| US-20250018014-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-16 | — | — | US | disclosed |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018014-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | MDM4 2942/4885TP53 2669/4885CASP3 1588/4885 |
| US-20250276995-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | VIP, IAPP, QPCT | MDM4 1915/4885TP53 930/4885CASP3 1555/4885 |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | MDM4 2942/4885TP53 2669/4885CASP3 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.